Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas

Summary Eight patients with malignant gliomas verified on CT scan, received an intravenous injection of 50 mg of Adriamycin R, 24 hours prior to surgical removal of the tumour. Peroperatively, both tumour and surrounding tissue specimens were obtained for determination of the tissue concentrations of Adriamycin and its reduced metabolite Adriamycinol. It was found that Adriamycin could be detected in tumour tissue from all patients. The concentration varied between 0,9 and 4,6 nmol/g tissue. In contrast, Adriamycin could only be detected in surrounding brain tissue from one patient.In anin vitro study a human malignant glioma cell line (U-251 MG) was exposed to various concentrations of Adriamycin for 24 hours. It was found that an intracellular drug concentration above 30 nmol/g cells caused a concentration dependent inhibition of cell growth. Thus, it is likely that the poor effect of Adriamycin on patients with malignant gliomas is due to an ineffective drug accumulation in the tumour tissue.     

pH值对IFN-α2b、rIL-2、ADM合用维拉帕米对人肝癌细胞杀伤作用的影响

目的　观察培养液在 pH值为 6 .8、7.3、7.6条件下rIL - 2、IFN -α2b、ADM及合用维拉帕米对人肝癌细胞 74 0 4杀伤作用的影响。方法　MTT法于 96孔培养板上进行杀伤实验 ,测定培养液pH值分别为 6 .8、7.3、7.6状态下 ,rIL - 2、IFN -α2b、ADM、及与维拉帕米联合杀伤人肝癌细胞 70 4 0的差异。结果　pH值为 7.6状态下rIL - 2、IFN -α2b、ADM及合用维拉帕米杀伤效果最佳。pH值为 6 .8、7.3、7.6时 ,IFN -α2b都能增加ADM抗肿瘤作用 ,但pH值为 7.6时 ,IFN -α2b +ADM杀伤效果最佳。结论　在偏硷性环境下 ,rIL - 2、IFN -α2b、ADM及合用维拉帕米对肿瘤细胞杀伤效果最佳     

前列腺素E1脂微球载体制剂对多柔比星肾病大鼠结缔组织生长因子表达的影响

目的研究多柔比星肾病大鼠肾组织中结缔组织生长因子(CTGF)表达,同时探讨前列腺素E1脂微球载体制剂(Lipo-PGE1)对其表达的影响.方法 将24只雌性SD大鼠(体重180～200 g)随机分为对照组、多柔比星肾病模型组和多柔比星肾病Lipo-PGE1治疗组3组.采用尾静脉一次性注射多柔比星7.5 mg/kg的方法建立多柔比星肾病动物模型,第8周开始Lipo-PGE1治疗组给予尾静脉注射Lipo-PGE1,用量200 μg/(kg*d).10周后处死全部大鼠,并观察肾组织病理改变,应用免疫组织化学方法和原位杂交技术检测CTGF在肾组织中的表达. 结果 Lipo-PGE1治疗组大鼠肾小球硬化及基质增生程度比多柔比星肾病组明显减轻,免疫组织化学染色及原位杂交结果显示多柔比星肾病组较正常对照组肾小球和肾小管区CTGF蛋白及CTGFmRNA表达量明显增加(P<0.05).Lipo-PGE1治疗组肾小球和肾小管间质CTGF蛋白及CTGFmRNA表达量明显低于多柔比星肾病组(P<0.05).结论 多柔比星肾病组大鼠第10周肾小球及肾小管间质尤其是肾小管间质区CTGF蛋白及CTGFmRNA表达量明显增加.Lipo-PGE1延缓多柔比星肾病肾损害,其机制可能与通过下调CTGF的表达有一定关系,并且可能通过减少肾小球内细胞增生和细胞外基质(ECM)沉积,延缓慢性肾脏疾病的进展.     

提高抗肝癌药物的肝脏浓度并降低心脏,血液浓度的实验研究

实验研究结果表明：阿霉素（ＡＤＭ）在采用推进法注射时，经肝血管或外周静脉途径二者的肝、心与血液浓度均无显著差别．如采用控速缓慢输注法，则经肝血管较经外周静脉在提高肝脏浓度方面具有显著效果，心脏内浓度也有一定程度降低。如在肝血管内输注时与血液净化联合应用，则更能提高上述要求。以上结果将为临床抗癌药介入治疗应用方法的开展提供依据和参考价值。     

Preparation and evaluation of temperature sensitive liposomes containing adriamycin and cytarabine

Temperature sensitive liposomes (TSL) containing adriamycin (ADM) and cytarabine (Ara-C) were prepared. ADM and Ara-C were selected as model compounds of amphiphilic and hydrophilic drug, respectively. Encapsulation efficiency of ADM entrapped into TSL was about twice greater than that of Ara-C. It might be due to different polarity of the drugs. Lipid compositions of TSL had no effect on the encapsulation efficiency of drugs. Thermal behavior of TSL using a differential scanning calorimetry (DSC) was also investigated. Phase transition temperature (T_c) of TSL was dependent on the lipid compositions of TSL.ADM broadened thermogram of TSL but Ara-C did not. However, T_c of TSL was not changed by any drug. Release rate of drugs was highly dependent on temperature. The release profile of ADM was similar to that of Ara-C. The maximum release rate of drugs from TSL was occurred at the near T_c and observed at 39–41°C for DPPC (Dipalmitoylphosphatidylcholine) only, 52–54°C for DSPC (Distearoylphosphatidylcholine) only, 41–43°C for DPPC and DSPC (3∶1), and 43–45°C for DPPC and DSPC (1∶1), respectively. Effect of human serum albumin (HSA) on the release rate of ADM was investigated. HSA had no significant effect on the release of ADM below T_c. However, ADM release from TSL was increased at the near and above T_c. The HSA-induced leakage of drug may result from the interaction of liposomal constituents with HSA structure at the near T_c. From the fact that the release profiles of ADM from freshly prepared TSL and stored TSL for 1 week at 4°C was not changed, the TSL was considered to be stable for at least 1 week at 4°C. Based on these findings, TSL may be useful to deliver drugs to preheated target sites due to its thermal behaviors.     

Chemo-endocrine therapy in patients with stage D2 prostate cancer

There have only been a few studies of chemo-endocrine therapy compared with endocrine therapy alone in newly diagnosed prostate cancer patients. We assessed the effects of these two therapies by comparing long-term survival rates. One hundred and twenty-nine patients were entered in this study between November 1977 and March 1992. Seventy-seven patients were treated with endocrine therapy alone. Other 52 patients received chemo-endocrine therapy, which included orchiectomy and/or diethylstilbestrol diphosphate (DES-DP) plus Cisplatin, with or without other cytotoxic agents. All patients had bone metastasis at the beginning of the study. There was a significant difference in survival between patients who received endocrine therapy and chemo-endocrine therapy (P = 0.0078). That is, survival rate was superior for the chemoendocrine therapy patients throughout the entire follow-up period. These data suggest that early chemo-endocrine therapy containing Cisplatin, with or without maintenance chemotherapy, is a potentially effective treatment for newly diagnosed metastatic prostate cancer and is worth further investigation via a randomized trial.     

辅酶Q10对大鼠阿霉素心脏毒性的保护作用

目的：研究辅酶Q10（CoQ10）对大鼠阿霉素心脏毒性的保护作用，并探讨可能的机理。方法：采用离体心脏灌流方法，实验分3组：对照组、阿霉素组、CoQ10组，监测大鼠心肌收缩幅度、冠脉流量、心电图的变化，并测定冠脉流出液肌酸磷酸激酶（CPK）活力和大鼠心肌丙二醛含量、超氧化物歧化酶、谷胱甘肽过氧化物酶（GSH-Px）活力以及电镜下超微结构的改变。结果：CoQ10可改善阿霉素引起的大鼠心肌收缩幅度、冠脉流量下降，减少心律失常的发生，降低冠脉流出液CPK活力；CoQ10组心肌丙二醛含量明显低于阿霉素组、SOD和GSH-Px活力高于阿霉素组，电镜下超微结构变化亦优于阿霉素组。结论：CoQ10对阿霉素引起的心脏毒性具有保护作用，其机理可能与CoQ10拮抗阿霉素的氧自由基损伤有关。     

阿霉素磁性明胶微球的研究

报告了阿霉素磁性明胶微球（Ａｄｒ－ＭＧ－ｍｓ）的制备与性质，研究了超细氧化铁粒子的合成和磁性明胶微球（ＭＧ－ｍｓ）在狗体内的栓塞效果。阿霉素磁性明胶微球由２％阿霉素（Ａｄｒ）、６８％明胶和３０％的磁铁粒子组成，微球的平均粒径为２２μｍ。在体外实验中，药物释放速度证明微球有缓释的性质。磁铁粒子的平均粒径约为１０ｎｍ，磁性明胶微球与￣（９９ｍ）Ｔｃ标记磁性明胶微球通过导管分别输入狗的肝动脉内进行栓塞，照相和血管造影显示在未加外磁场时磁性明胶微球在左右肝叶分布几乎相等，而在１２００高斯的外磁场作用下，靶部位肝左叶的微球分布是肝右叶的２．２５倍，而甲状腺、脑、心脏的微球很微量，结果表明磁性明胶微球在外磁场作用下是一个很好的治疗肝癌的栓塞剂。     

新型控释化疗系统的基础研究

研究一种新型的控释化疗系统聚-二聚酸一葵二酸一阿霉索(P(DA—SA)-阿霉索(在脑组织内的相容性、体内外释药特性及体外抑瘤特性。将空载体P(DA—SA)分别植入实验动物脑内，观察局部反应；用紫外线光谱测定P(DA—SA)-阿霉素在磷酸盐缓冲液及兔脑内的控释特性；流式细胞仪检测P(DA—SA)-阿霉索诱发的胶质瘤细胞株的凋亡。P(DA—SA)在兔脑内引起的反应较轻，与明胶海绵相比无明显差异。P(DA—SA)-阿霉素在体内外释药速率稳定，控释时间达3周。控释剂组的胶质瘤细胞凋亡率达69．9％，与对照组有明显差异。P(DA—SA)具有良好的组织相容性，P(DA—SA)-阿霉索控释剂在体内外的控释效果理想，杀伤效应明显，该控释化疗系统有很好的临床应用价值。     

Adriamycin-induced DNA strand breaks in HeLa and in P388 leukaemia cells detected using in situ nick translation

DNA strand breaks produced by adriamycin (ADR) were measured in HeLa cells and ADR-sensitive and -resistant P388 leukaemia cells, using the in situ nick translation method. The break sites in the DNA were translated artificially in the presence of Escherichia coli DNA polymerase I and 3H-labelled dTTP, and were visualized by autoradiographic observation of the grains. The DNA strand breaks in the HeLa cells increased in a dose-dependent manner, compared with findings in the untreated control cells, i.e., 15.2 fold at 20 micrograms/ml of ADR for 1 h. This level correlated with DNA single-strand breaks detected by the alkaline elution method. DNA breaks were also noted in the ADR-sensitive P388 cells, but in the ADR-resistant cells the level of DNA strand breaks was low. The enhanced cytotoxicity is apparently the consequence of the enhanced potential of ADR to cause breaks in the DNA strands. Our findings show that the survival response of the cells decreases and the level of DNA strand breaks increases following exposure to ADR. ADR resistance may be mediated by a reduction in the level of DNA strand breaks.